A
72.80
-0.45 (-0.61%)
| Penutupan Terdahulu | 73.25 |
| Buka | 73.46 |
| Jumlah Dagangan | 149,709 |
| Purata Dagangan (3B) | 624,063 |
| Modal Pasaran | 4,209,505,280 |
| Harga / Jualan (P/S) | 112.51 |
| Harga / Buku (P/B) | 9.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -211.46% |
| Margin Operasi (TTM) | -847.56% |
| EPS Cair (TTM) | -2.99 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -79.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.76% |
| Nisbah Semasa (MRQ) | 4.93 |
| Aliran Tunai Operasi (OCF TTM) | -114.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.43 M |
| Pulangan Atas Aset (ROA TTM) | -16.69% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Arcellx, Inc. | Menurun | Menaik |
AISkor Stockmoo
1.8
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.75 |
|
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 14.50% |
| % Dimiliki oleh Institusi | 102.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Aju Ib Investment Co., Ltd. | 30 Sep 2025 | 1,047,557 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 130.00 (Canaccord Genuity, 78.57%) | Beli |
| Median | 117.00 (60.71%) | |
| Rendah | 88.00 (Cantor Fitzgerald, 20.88%) | Pegang |
| Purata | 113.00 (55.22%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 83.23 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 08 Dec 2025 | 105.00 (44.23%) | Beli | 69.56 |
| Canaccord Genuity | 03 Nov 2025 | 130.00 (78.57%) | Beli | 86.13 |
| Stifel | 16 Oct 2025 | 129.00 (77.20%) | Beli | 88.85 |
| Cantor Fitzgerald | 09 Oct 2025 | 88.00 (20.88%) | Pegang | 88.39 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2025 | Pengumuman | Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition |
| 05 Nov 2025 | Pengumuman | Arcellx Provides Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Pengumuman | Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |